Even though the fusion oncoprotein in SS was identified over 25 years ago and there are multiple sites of post-translational modification present in the domains of wild-type SS18 and SSX1/2/4, little has been published about the impact of post-translational modifications on SS18-SSX and their therapeutic value [10, 11]. Here, SSX2 is linked to synovial sarcoma.